17β-Hydroxysteroid dehydrogenase inhibitors: a patent review

Importance of the field: 17β-Hydroxysteroid dehydrogenases (17β-HSDs) mainly catalyze the reduction of C17-ketosteroids to their corresponding hydroxylated forms as well as the reverse reaction (oxidation). Able to convert inactive or less active steroid hormones into more potent ones and vice versa, certain 17β-HSDs play a key role, especially in the regulation of estrogen and androgen levels. The therapeutic potential of this enzyme family, especially for the treatment of breast cancer, prostate cancer, acne and osteoporosis, then stimulated the development of inhibitors of 17β-HSDs and important progress was achieved over the last years. Areas covered in this review: This review article reports all patent applications related to the inhibitors of 17β-HSDs, including some articles needed to complement the information presented. What the reader will gain: Readers will be informed about the role and function of 17β-HSDs in the first section and about the history of inhibitor development in the second section. Furthermore, in the third and main section, the readers will learn about the structures of patented inhibitors originating from different companies and academic groups. Take home message: The increase in the number of 17β-HSD inhibitors reported in the last years augurs well for the future. The challenge is now to translate these results into clinical studies to allow determination of the therapeutic usefulness of 17β-HSD inhibitors.

[1]  P. Hurn,et al.  Sex, Sex Steroids, and Brain Injury , 2009, Seminars in reproductive medicine.

[2]  J. Simard,et al.  17beta-hydroxysteroid dehydrogenase (HSD)/17-ketosteroid reductase (KSR) family; nomenclature and main characteristics of the 17HSD/KSR enzymes. , 1999, Journal of molecular endocrinology.

[3]  M. Poutanen,et al.  Evaluation of inhibitors for 17β-hydroxysteroid dehydrogenase type 1 in vivo in immunodeficient mice inoculated with MCF-7 cells stably expressing the recombinant human enzyme , 2006, Molecular and Cellular Endocrinology.

[4]  H. Tutill,et al.  E-ring modified steroids as novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. , 2005, Journal of medicinal chemistry.

[5]  C. Rancourt,et al.  Relative involvement of three 17β-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors , 2009, Molecular and Cellular Endocrinology.

[6]  D. Poirier,et al.  Inhibitors of type II 17β-hydroxysteroid dehydrogenase , 2001, Molecular and Cellular Endocrinology.

[7]  W. Bremner,et al.  Androgens in Health and Disease , 2003, Contemporary Endocrinology.

[8]  J. Simard,et al.  The key role of 17 beta-hydroxysteroid dehydrogenases in sex steroid biology. , 1997, Steroids.

[9]  S. Bhasin,et al.  Selective androgen receptor modulators as function promoting therapies , 2009, Current opinion in clinical nutrition and metabolic care.

[10]  J. Simard,et al.  Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. , 2000, Journal of molecular endocrinology.

[11]  B. Potter,et al.  17β‐hydroxysteroid dehydrogenase Type 1, and not Type 12, is a target for endocrine therapy of hormone‐dependent breast cancer , 2008 .

[12]  Michael J. Reed,et al.  The design of novel 17β-hydroxysteroid dehydrogenase type 3 inhibitors , 2009, Molecular and Cellular Endocrinology.

[13]  F. Labrie,et al.  Androgen receptor antagonists (antiandrogens): structure-activity relationships. , 2000, Current medicinal chemistry.

[14]  E. Groman,et al.  Human placental 17beta-estradiol dehydrogenase: characterization and structural studies. , 1974, Recent progress in hormone research.

[15]  W. Scott,et al.  4,5-Disubstituted cis-pyrrolidinones as inhibitors of 17β-hydroxysteroid dehydrogenase II. Part 1: Synthetic approach , 2005 .

[16]  D. B. Hales,et al.  Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormones. , 2004, Endocrine reviews.

[17]  T. Penning,et al.  17β-Hydroxysteroid dehydrogenase: inhibitors and inhibitor design , 1996 .

[18]  J. Adamski,et al.  Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases , 2006, Molecular and Cellular Endocrinology.

[19]  J. Simard,et al.  Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. , 2003, Endocrine reviews.

[20]  P. Talalay,et al.  On the molecular specificity of steroid-enzyme combinations. The kinetics of β-hydroxysteroid dehydrogenase , 1955, Proceedings of the Royal Society of London. Series B - Biological Sciences.

[21]  S. Gobec,et al.  Inhibitors of 17-Hydroxysteroid Dehydrogenase Type 1 , 2008 .

[22]  R. Hartmann,et al.  Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. , 2008, Journal of medicinal chemistry.

[23]  H. Tutill,et al.  Design and validation of specific inhibitors of 17beta-hydroxysteroid dehydrogenases for therapeutic application in breast and prostate cancer, and in endometriosis. , 2008, Endocrine-related cancer.

[24]  F. Labrie,et al.  Localization of type 5 17β-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization , 2005, Cell and Tissue Research.

[25]  D. Poirier,et al.  Overview of a rational approach to design type I 17β-hydroxysteroid dehydrogenase inhibitors without estrogenic activity: chemical synthesis and biological evaluation , 1998, The Journal of Steroid Biochemistry and Molecular Biology.

[26]  J. Adamski,et al.  Perspectives in Understanding the Role of Human 17β‐Hydroxysteroid Dehydrogenases in Health and Disease , 2009, Annals of the New York Academy of Sciences.

[27]  F. Labrie,et al.  Androgen biosynthetic pathways in the human prostate. , 2008, Best practice & research. Clinical endocrinology & metabolism.

[28]  J. Adamski,et al.  A guide to 17beta-hydroxysteroid dehydrogenases. , 2001, Molecular and cellular endocrinology.

[29]  M. Poutanen,et al.  Human 17 beta-hydroxysteroid dehydrogenase type 1 and type 2 isoenzymes have opposite activities in cultured cells and characteristic cell- and tissue-specific expression. , 1996, The Biochemical journal.

[30]  D J Newman,et al.  The influence of natural products upon drug discovery. , 2000, Natural product reports.

[31]  D. Poirier.  Advances in development of inhibitors of 17beta hydroxysteroid dehydrogenases. , 2009, Anti-cancer agents in medicinal chemistry.

[32]  M. Negri,et al.  Design, synthesis, biological evaluation and pharmacokinetics of bis(hydroxyphenyl) substituted azoles, thiophenes, benzenes, and aza-benzenes as potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1). , 2008, Journal of medicinal chemistry.

[33]  D. Poirier.  Inhibitors of 17β-Hydroxysteroid Dehydrogenases , 2003 .

[34]  S. Andersson,et al.  17β-Hydroxysteroid Dehydrogenases: Physiological Roles in Health and Disease , 1998, Trends in Endocrinology & Metabolism.

[35]  R. Hartmann,et al.  Design, synthesis and biological evaluation of bis(hydroxyphenyl) azoles as potent and selective non-steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent diseases. , 2008, Bioorganic & medicinal chemistry.

[36]  Search for function and modulation of enzyme activity: The international workshop on 11beta and 17beta-hydroxysteroid dehydrogenases, 8–11 May 2005, Elmau Castle, Germany , 2006, Molecular and Cellular Endocrinology.

[37]  I. Takenaka,et al.  Identification of novel functional inhibitors of 17beta-hydroxysteroid dehydrogenase type III (17beta-HSD3). , 2005, The Prostate.

[38]  P. Härkönen,et al.  Control of cell proliferation by steroids: The role of 17HSDs , 2006, Molecular and Cellular Endocrinology.

[39]  D. Poirier,et al.  Steroids and combinatorial chemistry. , 2004, Journal of combinatorial chemistry.

[40]  K. Ando,et al.  Systemic distribution and tissue localizations of human 17beta-hydroxysteroid dehydrogenase type 12 , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[41]  J. Adamski,et al.  Integrated view on 17beta-hydroxysteroid dehydrogenases , 2009, Molecular and Cellular Endocrinology.

[42]  H. Tutill,et al.  Novel inhibitors of 17beta-hydroxysteroid dehydrogenase type 1: templates for design. , 2008, Bioorganic & medicinal chemistry.

[43]  M. Negri,et al.  New insights into the SAR and binding modes of bis(hydroxyphenyl)thiophenes and -benzenes: influence of additional substituents on 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitory activity and selectivity. , 2009, Journal of medicinal chemistry.

[44]  R. Strickler,et al.  Inactivation of human placental 17 beta,20 alpha-hydroxysteroid dehydrogenase by 16-methylene estrone, an affinity alkylator enzymatically generated from 16-methylene estradiol-17 beta. , 1983, The Journal of biological chemistry.

[45]  C. Zouboulis,et al.  Cutaneous androgen metabolism: basic research and clinical perspectives. , 2002, The Journal of investigative dermatology.

[46]  V. Jordan,et al.  Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. , 2003, Journal of medicinal chemistry.

[47]  P. Talalay,et al.  Enzymatic Formation of 3α-Hydroxysteroids , 1954, Nature.

[48]  K. Ryan,et al.  The interconversion of estrone and estradiol by human tissue slices. , 1953, Endocrinology.

[49]  R. Auchus,et al.  Solid-state NMR observation of cysteine and lysine Michael adducts of inactivated estradiol dehydrogenase. , 1988, The Journal of biological chemistry.

[50]  F. Labrie,et al.  Localization of type 7 17β-hydroxysteroid dehydrogenase in mouse tissues In situ hybridization studies , 2005, The Journal of Steroid Biochemistry and Molecular Biology.

[51]  T. Penning,et al.  Molecular endocrinology of hydroxysteroid dehydrogenases. , 1997, Endocrine reviews.

[52]  D. Poirier,et al.  Design and synthesis of bisubstrate inhibitors of type 1 17beta-hydroxysteroid dehydrogenase: overview and perspectives. , 2008, European journal of medicinal chemistry.

[53]  F. Labrie,et al.  The intracrine sex steroid biosynthesis pathways. , 2010, Progress in brain research.

[54]  V. Jordan,et al.  Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. , 2003, Journal of medicinal chemistry.

[55]  R. Hartmann,et al.  The role of the heterocycle in bis(hydroxyphenyl)triazoles for inhibition of 17β-Hydroxysteroid Dehydrogenase (17β-HSD) type 1 and type 2 , 2009, Molecular and Cellular Endocrinology.

[56]  H. Tutill,et al.  Modification of estrone at the 6, 16, and 17 positions: novel potent inhibitors of 17beta-hydroxysteroid dehydrogenase type 1. , 2006, Journal of medicinal chemistry.

[57]  D. Covey,et al.  Trifluoromethylacetylenic alcohols as affinity labels: inactivation of estradiol dehydrogenase by a trifluoromethylacetylenic secostradiol. , 1990, Journal of medicinal chemistry.

[58]  D. Poirier,et al.  Inhibition of type 2 17β-hydroxysteroid dehydrogenase by estradiol derivatives bearing a lactone on the D-ring: structure–activity relationships , 2004, Steroids.

[59]  J. Pasqualini.  The selective estrogen enzyme modulators in breast cancer: a review. , 2004, Biochimica et biophysica acta.

[60]  B. Potter,et al.  Focused Libraries of 16‐Substituted Estrone Derivatives and Modified E‐Ring Steroids: Inhibitors of 17ß‐Hydroxysteroid Dehydrogenase Type 1 , 2006, ChemMedChem.

[61]  N. Hamilton.  Therapeutic potential of steroids for CNS disorders , 2001 .

[62]  Takashi Suzuki,et al.  17β‐Hydroxysteroid Dehydrogenases in Human Breast Cancer , 2009, Annals of the New York Academy of Sciences.

[63]  C. Simons,et al.  Inhibitors of steroidogenesis as agents for the treatment of hormone-dependent cancers , 2001 .

[64]  B. McEwen,et al.  Estrogen actions in the central nervous system. , 1999, Endocrine reviews.

[65]  J. Adamski,et al.  A guide to 17β-hydroxysteroid dehydrogenases , 2001, Molecular and Cellular Endocrinology.

[66]  I. Takenaka,et al.  Identification of novel functional inhibitors of 17β‐hydroxysteroid dehydrogenase type III (17β‐HSD3) , 2005 .

[67]  K. Kavanagh,et al.  Structure and function of human 17beta-hydroxysteroid dehydrogenases. , 2006, Molecular and cellular endocrinology.

[68]  G. Ruigt,et al.  Short ReviewGlucocorticoid Receptor Antagonists: New Tools to Investigate Disorders Characterized by Cortisol Hypersecretion , 2004, Stress.

[69]  D. Poirier,et al.  Characteristics of human types 1, 2 and 3 17β-hydroxysteroid dehydrogenase activities: Oxidation/reduction and inhibition , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[70]  K. Harada,et al.  Coumarins as novel 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for potential treatment of prostate cancer. , 2010, Bioorganic & medicinal chemistry letters.

[71]  H. Tutill,et al.  Novel, potent inhibitors of 17β-hydroxysteroid dehydrogenase type 1 , 2006, Molecular and Cellular Endocrinology.

[72]  H. L. Carrell,et al.  Preparation of 14,15-secoestra-1,3,5(10)-trien-15-ynes, inhibitors of estradiol dehydrogenase , 1989, Steroids.

[73]  F. Labrie,et al.  Localization of Type 8 17β-hydroxysteroid Dehydrogenase mRNA in Mouse Tissues as Studied by In Situ Hybridization , 2005, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[74]  D. V. Vander Jagt,et al.  17-β-Hydroxysteroid dehydrogenase type 1: computational design of active site inhibitors targeted to the Rossmann fold , 2003 .

[75]  D. Poirier.  New cancer drugs targeting the biosynthesis of estrogens and androgens , 2008 .

[76]  V. Luu‐The.  Analysis and characteristics of multiple types of human 17β-hydroxysteroid dehydrogenase , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[77]  T. Penning,et al.  Mechanism based inhibition of hydroxysteroid dehydrogenases. , 1991, Journal of enzyme inhibition.

[78]  K. J. Ryan.  Steroid hormones. , 1978, Science.

[79]  P. Talalay,et al.  Specificity, kinetics, and inhibition of alpha- and beta-hydroxysteroid dehydrogenases. , 1956, The Journal of biological chemistry.

[80]  R. Hartmann,et al.  Selective inhibition of 17β-hydroxysteroid dehydrogenase type 1 (17βHSD1) reduces estrogen responsive cell growth of T47-D breast cancer cells , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[81]  P. Fuller,et al.  Structure-function relationships in the mineralocorticoid receptor. , 2008, Journal of molecular endocrinology.

[82]  R. Hartmann,et al.  Structure–activity study in the class of 6-(3′-hydroxyphenyl)naphthalenes leading to an optimization of a pharmacophore model for 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitors , 2009, Molecular and Cellular Endocrinology.

[83]  D. Poirier,et al.  Inhibitors of type II 17beta-hydroxysteroid dehydrogenase. , 2001, Molecular and cellular endocrinology.

[84]  D. Poirier,et al.  Steroidal lactones as inhibitors of 17beta-hydroxysteroid dehydrogenase type 5: chemical synthesis, enzyme inhibitory activity, and assessment of estrogenic and androgenic activities. , 2009, European journal of medicinal chemistry.

[85]  L. L. Engel,et al.  Human placental estradiol-17 beta dehydrogenase. I. Concentration, characterization and assay. , 1958, The Journal of biological chemistry.

[86]  R. Strickler,et al.  Inactivation of human placental 17 beta-estradiol dehydrogenase and 20 alpha-hydroxysteroid dehydrogenase with active site-directed 17 beta-propynyl-substituted progestin analogs. , 1982, The Journal of biological chemistry.

[87]  H. Tutill,et al.  Novel and potent 17beta-hydroxysteroid dehydrogenase type 1 inhibitors. , 2005, Journal of medicinal chemistry.

[88]  J. R. Hanson.  Steroids: partial synthesis in medicinal chemistry. , 2010, Natural product reports (Print).

[89]  R. Hartmann,et al.  Substituted 6-phenyl-2-naphthols. Potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1): design, synthesis, biological evaluation, and pharmacokinetics. , 2008, Journal of medicinal chemistry.

[90]  M. Poutanen,et al.  Human hydroxysteroid (17-beta) dehydrogenase 1 expression enhances estrogen sensitivity of MCF-7 breast cancer cell xenografts. , 2006, Endocrinology.

[91]  Takashi Suzuki,et al.  New development in intracrinology of breast carcinoma , 2006, Breast cancer.

[92]  R. Auchus,et al.  Mechanism-based inactivation of 17 beta,20 alpha-hydroxysteroid dehydrogenase by an acetylenic secoestradiol. , 1986, Biochemistry.

[93]  Pre-receptor steroid metabolism as target for pharmacological treatment , 2009, Molecular and Cellular Endocrinology.

[94]  Fernand Labrie,et al.  The key role of 17β-hydroxysteroid dehydrogenases in sex steroid biology , 1997, Steroids.

[95]  B. Husen,et al.  New inhibitors of 17β-hydroxysteroid dehydrogenase type 1 , 2006, Molecular and Cellular Endocrinology.

[96]  H. Zhang,et al.  Expression of aromatase and 17β-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study , 2006, The Journal of Steroid Biochemistry and Molecular Biology.

[97]  Erwin von Angerer,et al.  The Estrogen Receptor as a Target for Rational Drug Design , 1995 .

[98]  B. Potter,et al.  Development of hormone-dependent prostate cancer models for the evaluation of inhibitors of 17β-hydroxysteroid dehydrogenase Type 3 , 2009, Molecular and Cellular Endocrinology.

[99]  H. Tutill,et al.  The regulation and inhibition of 17β-hydroxysteroid dehydrogenase in breast cancer , 2006, Molecular and Cellular Endocrinology.

[100]  W. Scott,et al.  4,5-Disubstituted cis-pyrrolidinones as inhibitors of type II 17beta-hydroxysteroid dehydrogenase. Part 3. Identification of lead candidate. , 2006, Bioorganic & medicinal chemistry letters.

[101]  C. Labrie,et al.  Novel compounds inhibit estrogen formation and action. , 1992, Cancer research.